Inari Medical (NARI)

• Market cap: $2.96B
• 1 day: 2.68%
• 5 days: -2.11%
• 1 month: 12.71%
• 3 months: 1.83%
• 6 months: 7.60%
• Year to date: -23.11%
• 1 year: -17.17%
• 5 years: 18.94%
• 10 years: 18.94%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Employees: 1,300

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]

0.28% less ownership

Funds ownership: 93.93% [Q2] → 93.66% (-0.28%) [Q3]

7% less first-time investments, than exits

New positions opened: 40 | Existing positions closed: 43

1% less funds holding

Funds holding: 241 [Q2] → 238 (-3) [Q3]

14% less capital invested

Capital invested by funds: $2.63B [Q2] → $2.25B (-$378M) [Q3]

16% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 86

21% less call options, than puts

Call options by funds: $4.53M | Put options by funds: $5.72M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $46 9% downside
• Avg. target: $55 8% upside
• High target: $74 46% upside

8 analyst ratings

• positive: 2 25%
• neutral: 6 75%
• negative: 0 0%

Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target	1% downside $50	Hold Maintained	29 Oct 2024
Canaccord Genuity William Plovanic 67% 1-year accuracy 26 / 39 met price target	46% upside $74	Buy Maintained	29 Oct 2024
Baird David Rescott 81% 1-year accuracy 13 / 16 met price target	33% upside $67	Outperform Maintained	29 Oct 2024
Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target	3% upside $52	Neutral Maintained	29 Oct 2024
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target	9% downside $46	Hold Maintained	14 Oct 2024